Clinical Trials Logo

Clinical Trial Summary

Observational study to determine whether the proposed method of fFN specimen collection without a speculum is substantially equivalent to the approved method with a speculum examination when obtained at the gestational age of ≥ 24 weeks and ≤ 34, 6 days in symptomatic women and at the gestational age of ≥ 22 weeks, 0 days and ≤ 30, 6 days in asymptomatic women. A finding of substantial equivalency would support a modification to the labeling to allow the collection of specimens for fFN determination with or without a speculum examination.


Clinical Trial Description

The study population will include pregnant women who may be at risk for preterm delivery and require the fFN test, as determined by their doctor to aid in patient management. The subjects may or may not present with symptoms related to preterm labor and must satisfy the device's approved labeling and the eligibility criteria.

For pregnant women with signs of labor, the Fetal Fibronectin (fFN) test is approved for use as an aid to assess the risk of preterm delivery in ≤ 7 or ≤ 14 days from cervicovaginal sample collection that have intact amniotic membranes and minimal cervical dilation (< 3 cm) and are sampled between 24 weeks, 0 days and 34 weeks, 6 days. It is also approved for use with additional clinical information in asymptomatic women with singleton pregnancies when a sample is obtained during a routine prenatal visit between 22 weeks, 0 days and 30 weeks, 6 days of gestation.

The fFN test is run on The Rapid fFN for the TLiIQ® System and a positive fFN result occurs with concentrations ≥50ng/mL and a negative fFN test with concentrations <50ng/mL.

The current FDA-approved labeling for the collection of the fFN specimen requires a speculum examination; however, the collection of the fFN specimen is often needed when the women first arrives at the hospital labor and delivery unit, where nurses often are not trained or credentialed to perform speculum examinations and a physician may not be readily available to perform the collection. Therefore, there is an unmet need for a simpler collection method.

The test article in this study is the collection of cervicovaginal samples for fFN determination using a standardized collection method without a speculum. The control article in this study is the collection of a cervicovaginal sample for fFN determination using the approved collection method requiring a speculum examination. Both the test and control fFN specimen samples will be collected and evaluated using the approved Rapid fFN for the TLiIQ® System.

The primary objective of this study is to determine whether the proposed method of fFN specimen collection without a speculum is substantially equivalent to the approved method with a speculum examination when obtained at the gestational age of ≥ 24 weeks and ≤ 34, 6 days in symptomatic women and at the gestational age of ≥ 22 weeks, 0 days and ≤ 30, 6 days in asymptomatic women. A finding of substantial equivalency would support a modification to the labeling to allow the collection of specimens for fFN determination with or without a speculum examination.

Hypothesis: The method of fFN specimen collection without a speculum is not inferior to collection with a speculum within a 5% margin of non-inferiority. ;


Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT00883324
Study type Observational
Source Hologic, Inc.
Contact
Status Completed
Phase N/A
Start date March 2009

See also
  Status Clinical Trial Phase
Completed NCT03304782 - Fitbit Activity Tracker to Predict Risk of Preterm Birth
Recruiting NCT02420743 - Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery
Completed NCT01665378 - Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes N/A
Completed NCT01119963 - Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM) Phase 2/Phase 3
Completed NCT00141908 - Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate Phase 2
Recruiting NCT05278130 - Serial Screening and Treatment of Bacterial Vaginosis Trial N/A
Terminated NCT03596125 - Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP) Phase 2/Phase 3
Recruiting NCT03123926 - Spontaneous Preterm Birth Marker Test N/A
Completed NCT00201643 - A Randomized Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids (ACS) on Neonatal Outcome Phase 4
Completed NCT01353807 - Impact of Fish Oil Supplementation in 3rd Trimester of Pregnancy on Maternal and Offspring Health N/A
Terminated NCT02545127 - Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely Phase 2
Completed NCT02371356 - Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health
Active, not recruiting NCT01009723 - Preterm Delivery Risk Prediction by Measurement of Prenatal Serum Screening Markers N/A
Completed NCT00615550 - PREGNANT Short Cervix Trial Phase 3
Completed NCT02694679 - Randomized Controlled Trial of Social Network Targeting in Honduras N/A
Completed NCT01031017 - Prophylactic Administration of Natural Progesterone in the Prevention of Preterm Delivery in Twin Pregnancies Phase 4
Completed NCT00329914 - Does Progesterone Prevent Very Preterm Delivery in Twin Pregnancies? Phase 2
Completed NCT00331695 - Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Phase 4
Completed NCT01818518 - Neonatal Outcome by Reason for Delivery
Completed NCT04637880 - 25- Hydroxyvitamin D Levels in Pregnancy and Effects on Pregnancy Related Disorders